MLICM
GTBP icon

Metropolitan Life Insurance Company (MetLife)’s GT Biopharma GTBP Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-293
Closed -$136K – 2846
2021
Q2 		$136K Buy
+293
New +$122K ﹤0.01% 2420

Other funds holding GTBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s GTBP Position: Q3 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of GT Biopharma (GTBP) in Q3 2021, closing a stake of 293 shares — an estimated $136K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in GTBP in Q2 2021 and held it in 1 quarter. The position peaked at $136K in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q3 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining GT Biopharma position as of Q3 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 293 GT Biopharma shares in Q3 2021, an estimated $136K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in GT Biopharma in Q2 2021 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s GT Biopharma position peaked at $136K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2021, filed 15 Nov 2021.